Groundbreaking Covid study with Hispanics, Blacks, Native Americans shows varied results with Genentech drug
The 389-person clinical trial, which used the rheumatoid arthritis drug Actemra in patients with Covid-associated pneumonia, is part of a "call to action" for more-inclusive drug studies. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 18, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its Elecsys ® Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark. Roche has filed for Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA). The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can play an important part in characterising a vaccine-induced immune response.1 Specifically, the test targets antibodies which are directed against the ...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its Elecsys ® Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark. Roche has filed for Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA). The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can play an important part in characterising a vaccine-induced immune response.1 Specifically, the test targets antibodies which are directed against the ...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III EMPACTA study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Actemra ®/RoActemra® (tocilizumab) plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care (log-rank p-value = 0.0348; HR [95% CI] = 0.56 [0.32, 0.97]). The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra/RoActemra arm versus 19.3% in the placebo...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III EMPACTA study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Actemra ®/RoActemra® (tocilizumab) plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care (log-rank p-value = 0.0348; HR [95% CI] = 0.56 [0.32, 0.97]). The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra/RoActemra arm versus 19.3% in the placebo...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

Presagen develops algorithm to improve AI scalability
Presagen has developed a new algorithm that cleans poor-quality data automatically...Read more on AuntMinnie.comRelated Reading: C-MIMI: Use of AI in radiology is evolving Medical imaging AI market projected for strong growth How well does imaging AI perform in the real world? RSNA launches AI challenge to detect pneumonia on x-rays (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 16, 2020 Category: Radiology Source Type: news

What Are the Four Stages of Pneumonia
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 15, 2020 Category: General Medicine Source Type: news

Bronchitis in Childhood Tied to Worse Lung Health in Adulthood Bronchitis in Childhood Tied to Worse Lung Health in Adulthood
Children who suffer a bout of bronchitis at least once before their seventh birthday are at increased risk for developing lung problems such as asthma and pneumonia later in life, a study suggests.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 14, 2020 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news

Was I Misdiagnosed? Dr. Mallika Marshall Answers Your Coronavirus Questions
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p0").init({"mcp":"cbs","width":"100%","height":"100%","video":"4705035","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p0","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 11, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Syndicated Local Coronavirus Coronavirus Vaccine Dr. Mallika Marshall Source Type: news

CT radiomics predicts esophageal cancer outcomes
Machine-learning models that assess both peritumoral and intratumoral radiomics...Read more on AuntMinnie.comRelated Reading: PET radiomics tailor head/neck cancer treatment CT radiomics can predict COVID-19 pneumonia outcomes AI, radiomics can predict stroke treatment success Can radiomics improve CT lung cancer screening? AI can predict if COVID-19 patients will need ventilators (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 11, 2020 Category: Radiology Source Type: news

Vaccine proves effective against the most severe type of pneumonia
(Murdoch Childrens Research Institute) A pneumococcal vaccine was effective at protecting children in Laos against the most severe type of pneumonia, a new study has found. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2020 Category: International Medicine & Public Health Source Type: news

A case of chemical pneumonia caused by white electric oil poisoning - He J, Chen Y, Luo ZH, Jiang WZ, Wei HC.
The main component of white electric oil is "n-hexane" and other low-carbon alkanes organic components. Poisoning is more common in the nervous system damage caused by long-term inhalation, and acute lung damage caused by mistaken ingestion is rare. This a... (Source: SafetyLit)
Source: SafetyLit - September 9, 2020 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news

Miglustat improves swallowing in children and adolescents with Niemann-Pick type C1 disease
NIH observational study suggests that the drug may decrease risk of pneumonia and death in this population. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - September 9, 2020 Category: American Health Source Type: news

Implications of Obesity in Severe COVID-19 Pneumonia Implications of Obesity in Severe COVID-19 Pneumonia
In what ways might obesity impact outcomes of critically ill COVID-19 patients, and what are the potential implications for management?Critical Care Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 9, 2020 Category: Consumer Health News Tags: Critical Care Journal Article Source Type: news

Viral pneumonia: Symptoms, Causes And Treatment
Title: Viral pneumonia: Symptoms, Causes And TreatmentCategory: Diseases and ConditionsCreated: 9/9/2020 12:00:00 AMLast Editorial Review: 9/9/2020 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - September 9, 2020 Category: Respiratory Medicine Source Type: news

How Long Is Pneumonia Contagious?
Title: How Long Is Pneumonia Contagious?Category: Diseases and ConditionsCreated: 9/4/2020 12:00:00 AMLast Editorial Review: 9/4/2020 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - September 4, 2020 Category: Respiratory Medicine Source Type: news

Can Pneumonia Go Away On Its Own?
Title: Can Pneumonia Go Away On Its Own?Category: Diseases and ConditionsCreated: 9/4/2020 12:00:00 AMLast Editorial Review: 9/4/2020 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - September 4, 2020 Category: Respiratory Medicine Source Type: news

Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems
Basel, 04 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the cobas ® SARS-CoV-2& Influenza A/B Test for use on the cobas ® 6800/8800 Systems has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). This test is intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B in patients suspected by their healthcare provider of having respiratory viral infection consistent with COVID-19. Additionally, it is available in markets accepting the CE mark.“With the approaching flu season, this new...
Source: Roche Media News - September 4, 2020 Category: Pharmaceuticals Source Type: news

Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems
Basel, 04 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the cobas ® SARS-CoV-2& Influenza A/B Test for use on the cobas ® 6800/8800 Systems has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). This test is intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B in patients suspected by their healthcare provider of having respiratory viral infection consistent with COVID-19. Additionally, it is available in markets accepting the CE mark.“With the approaching flu season, this new...
Source: Roche Investor Update - September 4, 2020 Category: Pharmaceuticals Source Type: news

Factors that raise the risk of mortality among children with several acute malnutrition
(American Society for Nutrition) #AJCN review identifies independent predictors of inpatient mortality among children with severe acute malnutrition: HIV infection, diarrhea, pneumonia, shock, lack of appetite, and low weight-to-height ratio. The authors found that children with a low weight-to-height ratio at hospital admission were at highest risk of mortality. " Early recognition of these prognostic factors within the community, alongside risk stratification at hospital admission, may help reduce inpatient mortality among children with severe acute malnutrition, " said author Jonathan Sturgeon. (Source: EurekA...
Source: EurekAlert! - Social and Behavioral Science - September 4, 2020 Category: International Medicine & Public Health Source Type: news

Johnson & Johnson Announces that Janssen ’s COVID-19 Investigational Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies
Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2, the virus that causes COVID-19 in people. The data, published today in Nature Medicine, demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.This publication follows Johnson &...
Source: Johnson and Johnson - September 3, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Standardizing the approach to late onset sepsis in neonates through antimicrobial stewardship: a quality improvement initiative
Conclusion(s): Developing and engaging a NICU ASP team improves compliance with late onset sepsis guidelines through the implementation of a LOS bundle of care. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 3, 2020 Category: Consumer Health News Source Type: news

Investigational COVID-19 vaccine candidate prevents severe clinical disease in animals
(Beth Israel Deaconess Medical Center) In new research published in Nature Medicine, Beth Israel Deaconess Medical Center immunologist Dan H. Barouch, MD, PhD, and colleagues demonstrated that the optimal vaccine elicited robust immune response in Syrian golden hamsters and prevented severe clinical disease -- including weight loss, pneumonia and death. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 3, 2020 Category: International Medicine & Public Health Source Type: news

Corticosteroids improve survival in critically ill COVID-19 patients
(University of Pittsburgh) In a tremendous demonstration of global collaboration, clinician-scientists have pooled data from 121 hospitals in eight countries to find that inexpensive, widely available steroids improve the odds that very sick COVID-19 patients will survive the illness. The findings were made through the " Randomized Embedded Multifactorial Adaptive Platform-Community Acquired Pneumonia " (REMAP-CAP) trial and are reported today in JAMA as part of a four-article package. The World Health Organization is updating its COVID-19 treatment guidance as a result. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 2, 2020 Category: Infectious Diseases Source Type: news

In - Hospital Heart Failure Deaths Down With Routine Vaccinations
Patients with heart failure receiving flu, pneumonia vaccinations have lower in - hospital mortality (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 1, 2020 Category: Respiratory Medicine Tags: Cardiology, Family Medicine, Geriatrics, Gynecology, Infections, Internal Medicine, Nursing, Pharmacy, Pulmonology, Conference News, Source Type: news

GE unveils cardiac ultrasound package at ESC
GE Healthcare has launched a new cardiovascular ultrasound package based on...Read more on AuntMinnie.comRelated Reading: GE launches 7T MRI scanner at ISMRM 2020 GE, Osprey announce distribution deal GE Healthcare's Q2 revenue plummets 21% GE launches AI software for chest x-ray GE, Oxford to create COVID-19 pneumonia AI algorithms (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 1, 2020 Category: Radiology Source Type: news

Flu, Pneumonia Vaccines Save Lives of Heart Failure Patients: Study
(Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - August 28, 2020 Category: Respiratory Medicine Tags: Cardiology, Family Medicine, Infections, Pulmonology, News, Source Type: news

Flu, Pneumonia Vaccines Save Lives of Heart Failure Patients: Study
FRIDAY, Aug. 28, 2020 -- Flu and pneumonia vaccines lead to fewer hospital deaths among heart failure patients, a new study finds. " Our study provides further impetus for annual immunizations in patients with heart failure. Despite advice to do so,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 28, 2020 Category: General Medicine Source Type: news

Flu, Pneumonia Vaccines Save Lives of Heart Failure Patients: Study
Title: Flu, Pneumonia Vaccines Save Lives of Heart Failure Patients: StudyCategory: Health NewsCreated: 8/28/2020 12:00:00 AMLast Editorial Review: 8/28/2020 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - August 28, 2020 Category: Cardiology Source Type: news

Vaccines against respiratory infections linked with less heart failure deaths
(European Society of Cardiology) Influenza and pneumonia vaccinations are associated with fewer hospital deaths in patients with heart failure. That's the result of a study in nearly 3 million Americans released today at ESC Congress 2020. One out of five individuals will develop heart failure in their lifetime. An estimated 26 million people are affected worldwide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 28, 2020 Category: International Medicine & Public Health Source Type: news

DNR Orders in Patients With Community-Acquired Pneumonia DNR Orders in Patients With Community-Acquired Pneumonia
How common is it for patients hospitalized with community-acquired pneumonia to receive a DNR order? Are these orders associated with higher mortality?BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2020 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Respiratory follow-up of patients with COVID-19 pneumonia, Thorax
Review provides a structure for respiratory follow-up of patients with clinicoradiological confirmation of COVID-19 pneumonia. It defines two separate algorithms integrating disease severity, likelihood of long-term respiratory complications and functional capacity on discharge. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 27, 2020 Category: Consumer Health News Source Type: news

Recarbrio Effective for Hospital-Acquired Bacterial Pneumonia Recarbrio Effective for Hospital-Acquired Bacterial Pneumonia
Recarbrio is noninferior to piperacillin/tazobactam for treating adults with hospital-acquired or ventilator-associated bacterial pneumonia, according to results from the RESTORE-IMI 2 trial.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 26, 2020 Category: Intensive Care Tags: Pulmonary Medicine News Source Type: news

Exclusive: The Scientist Who Sequenced the First COVID-19 Genome Speaks Out About the Controversies Surrounding His Work
Over the past few years, Professor Zhang Yongzhen has made it his business to sequence thousands of previously unknown viruses. But he knew straight away that this one was particularly nasty. It was about 1:30 p.m. on Jan. 3 that a metal box arrived at the drab, beige buildings that house the Shanghai Public Health Clinical Center. Inside was a test tube packed in dry ice that contained swabs from a patient suffering from a peculiar pneumonia sweeping China’s central city of Wuhan. But little did Zhang know that that box would also unleash a vicious squall of blame and geopolitical acrimony worthy of Pandora herself....
Source: TIME: Health - August 25, 2020 Category: Consumer Health News Authors: Charlie Campbell / Shanghai Tags: Uncategorized COVID-19 overnight Source Type: news

Exclusive: The Chinese Scientist Who Sequenced the First COVID-19 Genome Speaks Out About the Controversies Surrounding His Work
Over the past few years, Professor Zhang Yongzhen has made it his business to sequence thousands of previously unknown viruses. But he knew straight away that this one was particularly nasty. It was about 1:30 p.m. on Jan. 3 that a metal box arrived at the drab, beige buildings that house the Shanghai Public Health Clinical Center. Inside was a test tube packed in dry ice that contained swabs from a patient suffering from a peculiar pneumonia sweeping China’s central city of Wuhan. But little did Zhang know that that box would also unleash a vicious squall of blame and geopolitical acrimony worthy of Pandora herself....
Source: TIME: Science - August 25, 2020 Category: Science Authors: Charlie Campbell / Shanghai Tags: Uncategorized COVID-19 overnight Source Type: news

Exclusive: The Chinese Scientist Who Sequenced the First COVID-19 Genome Speaks Out About the Controversies Surrounding His Work
Over the past few years, Professor Zhang Yongzhen has made it his business to sequence thousands of previously unknown viruses. But he knew straight away that this one was particularly nasty. It was about 1:30 p.m. on Jan. 3 that a metal box arrived at the drab, beige buildings that house the Shanghai Public Health Clinical Center. Inside was a test tube packed in dry ice that contained swabs from a patient suffering from a peculiar pneumonia sweeping China’s central city of Wuhan. But little did Zhang know that that box would also unleash a vicious squall of blame and geopolitical acrimony worthy of Pandora herself....
Source: TIME: Health - August 25, 2020 Category: Consumer Health News Authors: Charlie Campbell / Shanghai Tags: Uncategorized COVID-19 overnight Source Type: news

How Convalescent Plasma Could Help Fight COVID-19
The last time most of us gave any thought to antibodies was probably in high school biology, but we’re getting a crash refresher course thanks to COVID-19. They are, after all, the key to our best defenses against SARS-CoV-2, the virus that’s caused the global pandemic. People who have been infected likely rely on antibodies to recover, and antibodies are what vaccines are designed to produce. Or at least that’s what infectious-disease and public-health experts assume for now. Because SARS-CoV-2 is such a new virus, even the world’s best authorities aren’t yet sure what it will take to build p...
Source: TIME: Health - August 24, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Study: Remdesivir doesn't boost outcomes in moderate pneumonia from COVID-19
Remdesivir does not improve clinical outcomes in people hospitalized with moderate pneumonia from COVID-19, a study published Friday by JAMA Network Open found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 21, 2020 Category: Consumer Health News Source Type: news

Effect of remdesivir vs standard care on clinical status of patients with moderate COVID-19
(JAMA Network) This open-label randomized trial compares the effect of remdesivir (5 or 10 days) compared with standard care on clinical status 11 days after treatment initiation among patients with confirmed SARS-CoV-2 infection hospitalized with moderate pneumonia. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 21, 2020 Category: Infectious Diseases Source Type: news

3D CT models can help assess COVID-19 lung damage
Can advanced visualization techniques used to research the lungs of reptiles...Read more on AuntMinnie.comRelated Reading: Practices can 'recover wisely' from COVID-19 Contest offers $1.8M for COVID-19 CT research AI analyzes likelihood, extent of COVID-19 on chest CT CT radiomics can predict COVID-19 pneumonia outcomes What did radiologists miss while focused on COVID-19? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 20, 2020 Category: Radiology Source Type: news

Coronavirus deaths fall to ANOTHER low: Flu and pneumonia is now killing six times more people
Latest data from the Office for National Statistics revealed flu and pneumonia killed 1,013 people in England and Wales in the week up to August 7, compared to 152 Covid-19 victims. (Source: the Mail online | Health)
Source: the Mail online | Health - August 18, 2020 Category: Consumer Health News Source Type: news

Update of the Treatment of Nosocomial Pneumonia in the ICU Update of the Treatment of Nosocomial Pneumonia in the ICU
This article provides an update.Critical Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 14, 2020 Category: Consumer Health News Tags: Critical Care Journal Article Source Type: news

SARS-CoV-2 infection protects against rechallenge in rhesus macaques
An understanding of protective immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for vaccine and public health strategies aimed at ending the global coronavirus disease 2019 (COVID-19) pandemic. A key unanswered question is whether infection with SARS-CoV-2 results in protective immunity against reexposure. We developed a rhesus macaque model of SARS-CoV-2 infection and observed that macaques had high viral loads in the upper and lower respiratory tract, humoral and cellular immune responses, and pathologic evidence of viral pneumonia. After the initial viral clearance, animals were recha...
Source: ScienceNOW - August 13, 2020 Category: Science Authors: Chandrashekar, A., Liu, J., Martinot, A. J., McMahan, K., Mercado, N. B., Peter, L., Tostanoski, L. H., Yu, J., Maliga, Z., Nekorchuk, M., Busman-Sahay, K., Terry, M., Wrijil, L. M., Ducat, S., Martinez, D. R., Atyeo, C., Fischinger, S., Burke, J. S., Sle Tags: Immunology, Microbiology r-articles Source Type: news

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques
Coronavirus disease 2019 (COVID-19), which is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. It is unclear whether convalescing patients have a risk of reinfection. We generated a rhesus macaque model of SARS-CoV-2 infection that was characterized by interstitial pneumonia and systemic viral dissemination mainly in the respiratory and gastrointestinal tracts. Rhesus macaques reinfected with the identical SARS-CoV-2 strain during the early recovery phase of the initial SARS-CoV-2 infection did not show detectable viral dissemination, clinical manifest...
Source: ScienceNOW - August 13, 2020 Category: Science Authors: Deng, W., Bao, L., Liu, J., Xiao, C., Liu, J., Xue, J., Lv, Q., Qi, F., Gao, H., Yu, P., Xu, Y., Qu, Y., Li, F., Xiang, Z., Yu, H., Gong, S., Liu, M., Wang, G., Wang, S., Song, Z., Liu, Y., Zhao, W., Han, Y., Zhao, L., Liu, X., Wei, Q., Qin, C. Tags: Medicine, Diseases, Microbiology reports Source Type: news

New experimental coronavirus vaccine boosted antibody levels in mice 90-fold
After researchers sprayed the novel coronavirus into the noses of the mice, those who were immunized didn't develop pneumonia or have high level of particles in their lungs, (Source: the Mail online | Health)
Source: the Mail online | Health - August 12, 2020 Category: Consumer Health News Source Type: news

Experimental COVID-19 vaccine prevents severe disease in mice
(Washington University School of Medicine) Researchers at Washington University School of Medicine in St. Louis have created a COVID-19 vaccine candidate from a replicating virus. This experimental vaccine has proven effective at preventing pneumonia in mice. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 11, 2020 Category: Infectious Diseases Source Type: news

Tech Companies Are Transforming People ’s Bedrooms Into ‘Virtual Hospitals.’ Will It Last Post-COVID?
When Curtis Carlson started having back pain this spring, he tried to put off seeing a doctor. The COVID-19 pandemic was raging, his job at a transitional housing organization in Ukiah, Calif. was busier than ever amid the economic collapse, and a hospital seemed like the last place he wanted to be. But when he finally took himself to the emergency room and he was diagnosed with a kidney infection, Carlson figured he would have no choice but to stay. Instead, his doctors told him about a new program that would allow him to finish the rest of his hospital care at home, with a medical team monitoring him virtually around th...
Source: TIME: Health - August 10, 2020 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized COVID-19 Source Type: news

Boston Hospitals To Test Cystic Fibrosis Drug On Severely Ill Coronavirus Patients
BOSTON (CBS) — Harvard University researchers are working with two Boston hospitals to try a new way to help the sickest coronavirus patients. Boston Children’s Hospital and Brigham and Women’s Hospital will test a drug approved by the FDA to treat people with cystic fibrosis on those experiencing severe COVID-19 pneumonia and respiratory failure. The drug is called Dornase alfa, also known as DNase 1 or Pulmozyme, and it works to prevent lung infections by breaking up thick mucus. That may make oxygen easier to deliver via ventilator, researchers say. There’s also hope that the drug might break up ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 7, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Syndicated CBSN Boston Syndicated Local Boston Children's Hospital Brigham and Women's Hospital Coronavirus Harvard University Source Type: news

Kininogen supports inflammation and bacterial spreading during Streptococccus Pyogenes Sepsis
High-molecular-weight kininogen is a cofactor of the human contact system, an inflammatory response mechanism that is activated during sepsis. It has been shown that high-molecular-weight kininogen contributes to endotoxemia, but is not critical for local host defense during pneumonia by Gram-negative bacteria. However, some important pathogens, such as Streptococcus pyogenes, can cleave kininogen by contact system activation. Whether kininogen causally affects antibacterial host defense in S. pyogenes infection, remains unknown. Method(s): Kininogen concentration was determined in course plasma samples from septic patient...
Source: Current Awareness Service for Health (CASH) - August 5, 2020 Category: Consumer Health News Source Type: news

RSV vaccination of pregnant women could prevent pneumonia in babies
(University of the Witwatersrand) Professor Shabir A. Madhi of the University of the Witwatersrand, Johannesburg, is the lead author of a study published in the prestigious New England Journal of Medicine on Thursday, 30 July 2020.The multinational, multicentre study reports on the first RSV vaccine to provide evidence that inmunisation of pregnant woman could protect young infants under six months old against severe RSV lower respiratory tract infection (LRTI). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 1, 2020 Category: International Medicine & Public Health Source Type: news